Narlumosbart clinical trials
Narlumosbart is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Fudan University (1). The most-studied condition is NSCLC.
How Narlumosbart works
All drug targets →- Bone disorderPhase 3
- Giant cell tumorPhase 3
- Plasma cell myelomaPhase 3
- Non-small cell lung carcinomaPhase 2
- OsteoporosisPhase 2
- Hypercalcemia diseasePhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314993, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13084, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Narlumosbart
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Narlumosbart
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
NCT06738160 · ClinicalTrials.gov ↗ · NSCLC, Stereotactic Body Radiation Therapy (SBRT), Immunotherapy
|
Phase 2 | Recruiting | Fudan University | China |
|
A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone
NCT05813665 · ClinicalTrials.gov ↗ · Giant Cell Tumor of Bone
|
Phase 3 | Not yet open | Shanghai JMT-Bio Inc | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Narlumosbart
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Fudan University | 1 |
| Shanghai JMT-Bio Inc | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Narlumosbart trials
How many clinical trials are testing Narlumosbart?
2 current trials in our China register name Narlumosbart (also registered as JMT103) as a drug or biological intervention, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are Narlumosbart trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Narlumosbart clinical trials?
Fudan University (1) and Shanghai JMT-Bio Inc (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Narlumosbart works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Narlumosbart works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Narlumosbart (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.